Asset Details
Do you wish to reserve the book?
First‐In‐Human Study of Safety, Tolerability, Efficacy, and Pharmacokinetics of CPNE7‐Derived Peptide (Selcopintide) for Dentin Hypersensitivity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
First‐In‐Human Study of Safety, Tolerability, Efficacy, and Pharmacokinetics of CPNE7‐Derived Peptide (Selcopintide) for Dentin Hypersensitivity
Do you wish to request the book?
First‐In‐Human Study of Safety, Tolerability, Efficacy, and Pharmacokinetics of CPNE7‐Derived Peptide (Selcopintide) for Dentin Hypersensitivity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
First‐In‐Human Study of Safety, Tolerability, Efficacy, and Pharmacokinetics of CPNE7‐Derived Peptide (Selcopintide) for Dentin Hypersensitivity
2025
Overview
Dentin hypersensitivity is characterized by transient, sharp pain resulting from dentin exposure due to enamel or cementum loss. Current treatments, which primarily focus on superficial tubule occlusion or nerve desensitization, provide only temporary relief. Copine7 (CPNE7) induces odontoblast differentiation and physiologic dentin regeneration, enabling biological dentin sealing and presenting a novel therapeutic approach. This study reports the first‐in‐human results of a randomized, double‐blind, dose‐escalation phase 1/2a clinical trial evaluating the safety, tolerability, preliminary efficacy, and pharmacokinetics of the CPNE7‐derived functional peptide (selcopintide) in patients with dentin hypersensitivity. In Part A (Single Ascending Dose, SAD), 24 participants received a single topical application of selcopintide at ascending doses (2.5, 5, and 10 μg/tooth) in a 6:2 randomization ratio (treatment: placebo). In Part B (Multiple Ascending Dose, MAD), 16 participants received three topical applications (5 and 10 μg/tooth) over 15 days (day 1, 8, and 15; visits 2–4) with the same randomization ratio. Efficacy endpoints were assessed by changes in cold water, evaporative air, and tactile sensitivity. In Part B, the 10 μg selcopintide group demonstrated statistically significant reductions from the baseline across all three measures (p < 0.05), with a mean decrease of −23.2 ± 19.4 mm in VAS, the primary efficacy endpoint. All doses were well tolerated, with no serious adverse events and no detectable systemic absorption of selcopintide. These findings support the safety, tolerability, and preliminary efficacy of selcopintide as a novel therapeutic candidate for the treatment of dentin hypersensitivity.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Aged
/ Cementum
/ Dentin
/ Dentin Desensitizing Agents - administration & dosage
/ Dentin Desensitizing Agents - adverse effects
/ Dentin Desensitizing Agents - pharmacokinetics
/ Dentin Sensitivity - drug therapy
/ Dose-Response Relationship, Drug
/ efficacy
/ Female
/ Humans
/ Male
/ Peptides
/ Peptides - administration & dosage
/ Proteins
/ safety
/ Teeth
